MAP1LC3A and liver cancer: Consistent with the above results, using immunofluorescence to detect changes in LC3 levels, the results showed that silencing ORMDL3 can inhibit the autophagy level of liver cancer cells, and can also inhibit the autophagy induced by sorafenib in liver cancer cells (Fig. 3C, D).